CG
SAGE

Cutler Group’s Sage Therapeutics SAGE Stock Holding History

Cutler Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$3K Buy
+200
New +$4.61K ﹤0.01% 1748
2023
Q3 		– Sell
-8,080
Closed -$233K – 4257
2023
Q2 		$379K Buy
8,080
+180
+2% +$8.96K 0.05% 402
2023
Q1 		$331K Sell
7,900
-300
-4% -$12.9K 0.03% 476
2022
Q4 		$312K Hold
8,200
– – 0.03% 600
2022
Q3 		$321K Sell
8,200
-170
-2% -$6.57K 0.02% 727
2022
Q2 		$270K Sell
8,370
-2,065
-20% -$69.2K 0.02% 833
2022
Q1 		$345K Buy
10,435
+2,835
+37% +$107K 0.02% 850
2021
Q4 		$323K Buy
7,600
+720
+10% +$30.1K 0.01% 988
2021
Q3 		$304K Buy
6,880
+5,040
+274% +$231K 0.01% 1089
2021
Q2 		$104K Sell
1,840
-2,086
-53% -$147K ﹤0.01% 1846
2021
Q1 		$293K Buy
3,926
+3,002
+325% +$246K 0.01% 1029
2020
Q4 		$79K Buy
+924
New +$68.1K ﹤0.01% 1685
2020
Q3 		– Sell
-1,100
Closed -$55.7K – 5183
2020
Q2 		$45K Buy
+1,100
New +$39.9K ﹤0.01% 1818
2020
Q1 		– Sell
-3,671
Closed -$213K – 4552
2019
Q4 		$265K Buy
+3,671
New +$452K 0.02% 688
2018
Q3 		– Sell
-1,500
Closed -$232K – 4594
2018
Q2 		$234K Buy
1,500
+407
+37% +$63.9K 0.02% 719
2018
Q1 		$176K Buy
1,093
+3
+0.3% +$509 0.02% 888
2017
Q4 		$179K Sell
1,090
-1,421
-57% -$138K 0.01% 1035
2017
Q3 		$156K Sell
2,511
-29,031
-92% -$2.28M 0.01% 1339
2017
Q2 		$2.51M Buy
31,542
+31,022
+5,966% +$2.24M 0.09% 179
2017
Q1 		$36K Sell
520
-15,360
-97% -$900K ﹤0.01% 2724
2016
Q4 		$810K Sell
15,880
-543
-3% -$25.6K 0.03% 482
2016
Q3 		$756K Sell
16,423
-3,245
-16% -$132K 0.03% 435
2016
Q2 		$592K Buy
19,668
+17,368
+755% +$579K 0.03% 504
2016
Q1 		$73K Buy
2,300
+300
+15% +$10.6K ﹤0.01% 1923
2015
Q4 		$116K Buy
+2,000
New +$99.1K 0.01% 1627

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cutler Group's SAGE Position: Q1 2024 in Review

Cutler Group opened a new position in Sage Therapeutics (SAGE) in Q1 2024: 200 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #1748 among its holdings. This is a return to the name: Cutler Group previously reported a position in SAGE as recently as Q2 2023.

Cutler Group first reported a position in SAGE in Q4 2015 and has held it in 25 quarters since. The position peaked at $2.51M in Q2 2017. 205 funds tracked by Wall St. Rank hold SAGE as of Q1 2024.

  • Cutler Group held 200 shares of Sage Therapeutics worth $3K as of Q1 2024.
  • Sage Therapeutics was a new Cutler Group position in Q1 2024.
  • Sage Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1748 holding.
  • Cutler Group first reported a position in Sage Therapeutics in Q4 2015 and has held it in 25 quarters since.
  • Cutler Group's Sage Therapeutics position peaked at $2.51M in Q2 2017.
  • 205 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.